Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Assets (2021 - 2025)

Historic Return on Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to 0.47%.

  • 4D Molecular Therapeutics' Return on Assets fell 2300.0% to 0.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.47%, marking a year-over-year decrease of 2300.0%. This contributed to the annual value of 0.36% for FY2024, which is 200.0% down from last year.
  • 4D Molecular Therapeutics' Return on Assets amounted to 0.47% in Q3 2025, which was down 2300.0% from 0.4% recorded in Q2 2025.
  • 4D Molecular Therapeutics' Return on Assets' 5-year high stood at 0.18% during Q2 2024, with a 5-year trough of 0.47% in Q3 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' median Return on Assets value was 0.28% (recorded in 2024), while the average stood at 0.3%.
  • In the last 5 years, 4D Molecular Therapeutics' Return on Assets skyrocketed by 2200bps in 2024 and then crashed by -2300bps in 2025.
  • 4D Molecular Therapeutics' Return on Assets (Quarter) stood at 0.24% in 2021, then plummeted by -65bps to 0.4% in 2022, then grew by 28bps to 0.29% in 2023, then rose by 4bps to 0.28% in 2024, then tumbled by -69bps to 0.47% in 2025.
  • Its Return on Assets was 0.47% in Q3 2025, compared to 0.4% in Q2 2025 and 0.33% in Q1 2025.